These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32939957)

  • 1. High expression of a vascular stricture-related marker is predictive of an early response to tolvaptan, and a low fractional excretion of sodium is predictive of a poor long-term survival after tolvaptan administration for liver cirrhosis.
    Adachi T; Takaki A; Sato S; Tobita H; Kobashi H; Kinomura M; Nakatsuka A; Oyama A; Wada N; Sakata M; Takeuchi Y; Yasunaka T; Onishi H; Shiraha H; Okada H
    Hepatol Res; 2020 Dec; 50(12):1347-1354. PubMed ID: 32939957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites.
    Uojima H; Kinbara T; Hidaka H; Sung JH; Ichida M; Tokoro S; Masuda S; Takizawa S; Sasaki A; Koizumi K; Egashira H; Kako M
    Hepatol Res; 2017 Mar; 47(3):E14-E21. PubMed ID: 27059410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
    Kawaratani H; Fukui H; Moriya K; Noguchi R; Namisaki T; Uejima M; Kitade M; Takeda K; Okura Y; Kaji K; Nishimura N; Takaya H; Aihara Y; Sawada Y; Sato S; Seki K; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2017 Aug; 47(9):854-861. PubMed ID: 27704665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.
    Adachi T; Takeuchi Y; Takaki A; Oyama A; Wada N; Onishi H; Shiraha H; Okada H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.
    Tahara T; Mori K; Mochizuki M; Ishiyama R; Noda M; Hoshi H; Lefor AK; Shinozaki S
    Biomed Rep; 2017 Dec; 7(6):558-562. PubMed ID: 29250327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.
    Akiyama S; Ikeda K; Sezaki H; Fukushima T; Sorin Y; Kawamura Y; Saitoh S; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Hepatol Res; 2015 Nov; 45(11):1062-70. PubMed ID: 25429910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    Atsukawa M; Tsubota A; Kato K; Abe H; Shimada N; Asano T; Ikegami T; Koeda M; Okubo T; Arai T; Nakagawa-Iwashita A; Yoshida Y; Hayama K; Itokawa N; Kondo C; Chuganji Y; Matsuzaki Y; Iwakiri K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1256-1263. PubMed ID: 29215154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.
    Kogiso T; Yamamoto K; Kobayashi M; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Hepatol Res; 2017 Aug; 47(9):835-844. PubMed ID: 27670393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis.
    Uchida Y; Inao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Sugawara K; Nakao M; Nakayama N; Imai Y; Tomiya T; Mochida S
    Hepatol Res; 2020 Dec; 50(12):1355-1364. PubMed ID: 32886950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
    Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
    J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M
    Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.